<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191216045758N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-21</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the Effect of the Drug "Mumiaee" on the Union Period of Distal Radius Fractures</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of the Drug "Mumiaee" on the Union Period of Distal Radius Fractures: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50448</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The randomization method of this clinical trial is "Blocked". The type of this research is "Superiority" and is evaluated via "Parallel" method. By using Random Allocation Software, random blocks ,with variable sizes of 4 and 6, containing equal number of each group are designed. The arrangement of contents in each block ensures the equilibrium allocation of individuals in the study groups. By  patients' visits, one of the blocks is randomly chosen (via shuffling) and the patients are assigned to the groups of the study based on the content order of the block. Whenever the contents of the block, based on its size, are finished, a new block will be randomly chosen to cover the other patients and this process is repeated until all the patients are assigned to groups, Blinding description: In this study, the participants and the principle researcher (the treating physician), the researcher responsible for collecting the data and the assessors of the results are blinded. The final analyzers of data, the ones writing the final article and Data Safety and Monitoring Committee are not blinded. In order to blind the study, a person who is not involved in the study, will randomly open a block by each patient visit and will draw a card based on the order of content of the block and give it to the patient. These cards are coded by color into groups A and B. One of the researchers of the study who is not blinded will later give the drug or the placebo to the patients based on the codes assigned. Therefore this study is three way blinded.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: Distal Right Radius Fracture. Condition 2: Distal Left Radius Fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: consists of 22 patients who will receive 4 capsules of Mumiaee (Shilajit) containing 250 mg of the substance (a total of 1000 mg per day) every 6 hours, daily for 1 month. This medicine is produced in Pharmacological Herbs Research Institute of Mashhad University of Medical Sciences. Mumiaee (Shilajit) has been commonly used in tradition medicine over the years. This substance consists of Amino Acids, Albominoids, Fatty Resinoic Acids, Benzoic  Acid, Hippuric Acid. The most important substance in this medicine is Fulvic Acid which has anti-inflammatory and anti-oxidant effects. Mumiaee also contains mineral such as Copper, Magnesium, Calcium, Manganese, Nickel, Iron, Zinc, Lithium and Molybdenum. Intervention 2: Control group: consists of 22 Patients who will recieve 4 placebo capsules, containing 100 mg of Avisel Powder, every 6 hours daily for 1 month. Avisel Powder consists of Microcrystalline Cellulose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data potentially can be shared after anonymization of the participants.

When:
Data access allowed 6 months after publication of the research

To whom:
Researchers working in academic and scientific institutes

Conditions:
With the permission of the author, there is no problem with using the documentation.

Where to obtain:
Kimia Emami 
Email: kimia.emami.96@gmail.com
Dr. Ali Moradi (MD, PhD) 
Email: almor0012@gmail.com

How to obtain:
The document can be sent in less than one month via email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Orthopedic Surgery Department, Emam Reza Hospital, Emam Reza Square, Ebne Sina Street.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٣٧٩١٣٣١۶</zip>
        <telephone>+98 51 3854 3031</telephone>
        <email>moradial@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Orthopedic Surgery Department, Emam Reza Hospital, Emam Reza Square, Ebne Sina Street.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٣٧٩١٣٣١۶</zip>
        <telephone>+98 51 3854 3031</telephone>
        <email>moradial@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Closed Fractures
Fernandez Fractures type 1-3 that are fixed by PCP or External Fixators.
Lack of Rheumatoid Disease, Diabetes and Immune Deficiency in the past medical history of the participants.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pathological Fractures
Underlying Bones Diseases such as Osteopetrosis
Unexpected Special Medical Conditions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S52.501A</hc_code>
      <hc_code>S52.502A</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified fracture of the lower end of right radius, initial encounter for closed fracture</hc_keyword>
      <hc_keyword>Unspecified fracture of the lower end of left radius, initial encounter for closed fracture</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: consists of 22 patients who will receive 4 capsules of Mumiaee (Shilajit) containing 250 mg of the substance (a total of 1000 mg per day) every 6 hours, daily for 1 month. This medicine is produced in Pharmacological Herbs Research Institute of Mashhad University of Medical Sciences. Mumiaee (Shilajit) has been commonly used in tradition medicine over the years. This substance consists of Amino Acids, Albominoids, Fatty Resinoic Acids, Benzoic  Acid, Hippuric Acid. The most important substance in this medicine is Fulvic Acid which has anti-inflammatory and anti-oxidant effects. Mumiaee also contains mineral such as Copper, Magnesium, Calcium, Manganese, Nickel, Iron, Zinc, Lithium and Molybdenum.</i_keyword>
      <i_keyword>Control group: consists of 22 Patients who will recieve 4 placebo capsules, containing 100 mg of Avisel Powder, every 6 hours daily for 1 month. Avisel Powder consists of Microcrystalline Cellulose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Union Period of Distal Radius Fracture. Timepoint: At the beginning of the study and on the weeks 2, 4, 6, 8, 10, 12. Method of measurement: Wrist X-Ray.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wrist Range of Motion. Timepoint: On the weeks: 2, 4, 6, 8, 10 and 12. Method of measurement: By using Goniometer.</sec_outcome>
      <sec_outcome>Wrist Pain and Disability in Activities of Daily Living. Timepoint: After the initial treatment and the start of Mumiaee (Shilajit) consumption on the weeks 6 and 12. Method of measurement: By using Patient-Rated Wrist Evaluation questionnaire.</sec_outcome>
      <sec_outcome>Physical Function of Upper Limb. Timepoint: At the start of Mumiaee (Shilajit) consumption on the weeks 6 and 12. Method of measurement: By using Quick Disabilities of Arm, Shoulder and Hand questionnaire.</sec_outcome>
      <sec_outcome>Patient's Wrist Pain. Timepoint: At the start of Mumiaee (Shilajit) consumption on the weeks 6 and 12. Method of measurement: By Visual Analog Scale Pain questionnaire.</sec_outcome>
      <sec_outcome>Hand Grip Strength. Timepoint: After the initial treatment and the start of Mumiaee (Shilajit) consumption on the weeks 6 and 12. Method of measurement: By Orthopedic Equipment Dynamometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-11</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Medicine Faculty, Ferdowsi University of Mashhad, Azadi Square. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
